The week that was: PVR, Dr Reddy’s and HCL Tech among 10 names that buzzed during the week

NEW DELHI: Bluechip indices consolidated for the third week on the trot, closing flat, while broader markets outperformed their headline peers as they surged up to 5 per cent thanks to the multicap fund rule tweaks. IT and pharma names were in heavy demand and they supported the major indices …

Read moreThe week that was: PVR, Dr Reddy’s and HCL Tech among 10 names that buzzed during the week

Pharma stocks today have their best day in over a month. Cipla, Dr Reddy’s surge

Indian stock markets gave up early gains to end lower today, led by losses in banking stocks. On the other hand, gains in pharma stocks helped cap losses. The blue-chip NSE Nifty 50 index closed 0.1% lower at 11,504.95, while the benchmark S&P BSE Sensex, which has fewer pharma components, …

Read morePharma stocks today have their best day in over a month. Cipla, Dr Reddy’s surge

Dr Reddy’s string of announcements fail to impress analysts; stock could fall 30%

NEW DELHI: In a string of announcements over the last three days, Dr Reddy’s Labs has settled patent litigation with Celgene, launched an over-the-counter eye drop in the US and sealed the deal to bring Russian Covid-19 vaccine to India. Thanks to these, shares of the company have also appreciated. …

Read moreDr Reddy’s string of announcements fail to impress analysts; stock could fall 30%

Dr Reddy’s Revlimid settlement to boost US earnings beyond FY23

Dr Reddy’s Laboratories’ settlement with Celgene on Revlimid patents is a positive, and will open up opportunities in the US market, post-FY23. After several favourable rulings in the US recently, including this, the stock has been on the climb in the past month gaining 22%. But with today’s gains of …

Read moreDr Reddy’s Revlimid settlement to boost US earnings beyond FY23

Dr Reddy’s Lab shares today hit new highs, extend weekly gains to 20%

Shares of Dr Reddy’s Laboratories today jumped as much as 10% to extend its weekly gains to 20% after the drugmaker settled a patent litigation with Celgene, a unit of U.S.-based Bristol-Myers Squibb Co. Analysts at BofA Securities upgraded Dr Reddy’s Laboratories to “buy” from “neutral” after the news, saying …

Read moreDr Reddy’s Lab shares today hit new highs, extend weekly gains to 20%